Balance Sheet
Cash Flow Statement
AmortizationAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Change in Accured Expenses (2023 - 2025)

Historic Change in Accured Expenses for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $299.0 million.

  • Genmab A's Change in Accured Expenses rose 62926.83% to $299.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $392.0 million, marking a year-over-year increase of 22131.15%. This contributed to the annual value of $1.1 billion for FY2025, which is 11860.94% up from last year.
  • Genmab A's Change in Accured Expenses amounted to $299.0 million in Q4 2025, which was up 62926.83% from $602.0 million recorded in Q3 2025.
  • In the past 5 years, Genmab A's Change in Accured Expenses ranged from a high of $602.0 million in Q3 2025 and a low of -$28.0 million during Q3 2024
  • Moreover, its 3-year median value for Change in Accured Expenses was $80.0 million (2024), whereas its average is $215.2 million.
  • In the last 5 years, Genmab A's Change in Accured Expenses plummeted by 8801.17% in 2024 and then soared by 225000.0% in 2025.
  • Over the past 3 years, Genmab A's Change in Accured Expenses (Quarter) stood at $342.0 million in 2023, then tumbled by 88.01% to $41.0 million in 2024, then soared by 629.27% to $299.0 million in 2025.
  • Its Change in Accured Expenses stands at $299.0 million for Q4 2025, versus $602.0 million for Q3 2025 and $567.0 million for Q2 2025.